nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—kidney cancer—urinary bladder cancer	0.757	1	CtDrD
Everolimus—MTOR—prostate gland—urinary bladder cancer	0.00285	0.084	CbGeAlD
Everolimus—FKBP1A—prostate gland—urinary bladder cancer	0.00256	0.0756	CbGeAlD
Everolimus—MTOR—seminal vesicle—urinary bladder cancer	0.00241	0.0711	CbGeAlD
Everolimus—CYP3A4—urine—urinary bladder cancer	0.00233	0.0688	CbGeAlD
Everolimus—FKBP1A—seminal vesicle—urinary bladder cancer	0.00217	0.0639	CbGeAlD
Everolimus—MTOR—epithelium—urinary bladder cancer	0.00209	0.0617	CbGeAlD
Everolimus—MTOR—smooth muscle tissue—urinary bladder cancer	0.00202	0.0595	CbGeAlD
Everolimus—MTOR—renal system—urinary bladder cancer	0.00194	0.0573	CbGeAlD
Everolimus—FKBP1A—epithelium—urinary bladder cancer	0.00188	0.0555	CbGeAlD
Everolimus—FKBP1A—smooth muscle tissue—urinary bladder cancer	0.00181	0.0535	CbGeAlD
Everolimus—FKBP1A—renal system—urinary bladder cancer	0.00175	0.0515	CbGeAlD
Everolimus—FKBP1A—urethra—urinary bladder cancer	0.00171	0.0506	CbGeAlD
Everolimus—MTOR—female reproductive system—urinary bladder cancer	0.00155	0.0459	CbGeAlD
Everolimus—MTOR—vagina—urinary bladder cancer	0.00141	0.0415	CbGeAlD
Everolimus—FKBP1A—female reproductive system—urinary bladder cancer	0.0014	0.0412	CbGeAlD
Everolimus—FKBP1A—vagina—urinary bladder cancer	0.00126	0.0373	CbGeAlD
Everolimus—MTOR—lymph node—urinary bladder cancer	0.000909	0.0268	CbGeAlD
Everolimus—FKBP1A—lymph node—urinary bladder cancer	0.000818	0.0241	CbGeAlD
Everolimus—CYP3A4—renal system—urinary bladder cancer	0.00057	0.0168	CbGeAlD
Everolimus—CYP3A4—female reproductive system—urinary bladder cancer	0.000457	0.0135	CbGeAlD
Everolimus—MTOR—Signaling by EGFR—CDKN1A—urinary bladder cancer	5.6e-05	0.000849	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—HRAS—urinary bladder cancer	5.59e-05	0.000847	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—urinary bladder cancer	5.59e-05	0.000847	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—PTEN—urinary bladder cancer	5.59e-05	0.000847	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—SRC—urinary bladder cancer	5.59e-05	0.000847	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—CDKN1A—urinary bladder cancer	5.55e-05	0.000842	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—PTEN—urinary bladder cancer	5.54e-05	0.00084	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—CDKN1A—urinary bladder cancer	5.53e-05	0.000838	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—PTEN—urinary bladder cancer	5.52e-05	0.000836	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—urinary bladder cancer	5.51e-05	0.000835	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—EGFR—urinary bladder cancer	5.5e-05	0.000834	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	5.32e-05	0.000807	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—EGFR—urinary bladder cancer	5.26e-05	0.000798	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IFNA2—urinary bladder cancer	5.24e-05	0.000795	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—CDKN1A—urinary bladder cancer	5.23e-05	0.000793	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—SRC—urinary bladder cancer	5.23e-05	0.000793	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—PTEN—urinary bladder cancer	5.22e-05	0.000791	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	5.21e-05	0.000789	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—HRAS—urinary bladder cancer	5.2e-05	0.000788	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—KRAS—urinary bladder cancer	5.2e-05	0.000787	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—SRC—urinary bladder cancer	5.18e-05	0.000786	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—EGFR—urinary bladder cancer	5.18e-05	0.000785	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—HRAS—urinary bladder cancer	5.16e-05	0.000782	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—SRC—urinary bladder cancer	5.14e-05	0.000779	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—SRC—urinary bladder cancer	5.12e-05	0.000775	CbGpPWpGaD
Everolimus—MTOR—Disease—LIG1—urinary bladder cancer	5.09e-05	0.000771	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	5.04e-05	0.000764	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—CDKN2A—urinary bladder cancer	5.02e-05	0.000761	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—CDKN1A—urinary bladder cancer	5.01e-05	0.000759	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PTEN—urinary bladder cancer	5e-05	0.000757	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—KRAS—urinary bladder cancer	4.97e-05	0.000753	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—S100B—urinary bladder cancer	4.96e-05	0.000751	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—EGFR—urinary bladder cancer	4.95e-05	0.00075	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—EGFR—urinary bladder cancer	4.92e-05	0.000746	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—urinary bladder cancer	4.92e-05	0.000746	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	4.92e-05	0.000745	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—EGFR—urinary bladder cancer	4.9e-05	0.000742	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—KRAS—urinary bladder cancer	4.89e-05	0.000742	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	4.89e-05	0.000741	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—EGFR—urinary bladder cancer	4.87e-05	0.000739	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—RHOA—urinary bladder cancer	4.87e-05	0.000738	CbGpPWpGaD
Everolimus—MTOR—Immune System—BIRC3—urinary bladder cancer	4.85e-05	0.000735	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—urinary bladder cancer	4.8e-05	0.000728	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—KRAS—urinary bladder cancer	4.67e-05	0.000708	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—urinary bladder cancer	4.65e-05	0.000705	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—KRAS—urinary bladder cancer	4.65e-05	0.000705	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—SRC—urinary bladder cancer	4.63e-05	0.000702	CbGpPWpGaD
Everolimus—Jaundice—Doxorubicin—urinary bladder cancer	4.63e-05	0.000324	CcSEcCtD
Everolimus—Stomatitis—Doxorubicin—urinary bladder cancer	4.63e-05	0.000324	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—KRAS—urinary bladder cancer	4.63e-05	0.000701	CbGpPWpGaD
Everolimus—Rhinitis—Epirubicin—urinary bladder cancer	4.62e-05	0.000323	CcSEcCtD
Everolimus—Body temperature increased—Etoposide—urinary bladder cancer	4.61e-05	0.000323	CcSEcCtD
Everolimus—Abdominal pain—Etoposide—urinary bladder cancer	4.61e-05	0.000323	CcSEcCtD
Everolimus—Conjunctivitis—Doxorubicin—urinary bladder cancer	4.61e-05	0.000323	CcSEcCtD
Everolimus—Urinary tract infection—Doxorubicin—urinary bladder cancer	4.61e-05	0.000323	CcSEcCtD
Everolimus—Hepatitis—Epirubicin—urinary bladder cancer	4.61e-05	0.000322	CcSEcCtD
Everolimus—Haemorrhage—Epirubicin—urinary bladder cancer	4.61e-05	0.000322	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—KRAS—urinary bladder cancer	4.6e-05	0.000698	CbGpPWpGaD
Everolimus—Eye disorder—Methotrexate—urinary bladder cancer	4.6e-05	0.000322	CcSEcCtD
Everolimus—Diarrhoea—Fluorouracil—urinary bladder cancer	4.6e-05	0.000322	CcSEcCtD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—urinary bladder cancer	4.58e-05	0.000695	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—EGFR—urinary bladder cancer	4.58e-05	0.000695	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—EGFR—urinary bladder cancer	4.58e-05	0.000695	CbGpPWpGaD
Everolimus—Hypoaesthesia—Epirubicin—urinary bladder cancer	4.58e-05	0.000321	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—RBX1—urinary bladder cancer	4.58e-05	0.000694	CbGpPWpGaD
Everolimus—Asthenia—Cisplatin—urinary bladder cancer	4.57e-05	0.00032	CcSEcCtD
Everolimus—Pharyngitis—Epirubicin—urinary bladder cancer	4.57e-05	0.00032	CcSEcCtD
Everolimus—Cardiac disorder—Methotrexate—urinary bladder cancer	4.57e-05	0.00032	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—CXCL8—urinary bladder cancer	4.56e-05	0.000691	CbGpPWpGaD
Everolimus—Urinary tract disorder—Epirubicin—urinary bladder cancer	4.55e-05	0.000318	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—EGFR—urinary bladder cancer	4.54e-05	0.000689	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—urinary bladder cancer	4.54e-05	0.000688	CbGpPWpGaD
Everolimus—Oedema peripheral—Epirubicin—urinary bladder cancer	4.54e-05	0.000318	CcSEcCtD
Everolimus—Haematuria—Doxorubicin—urinary bladder cancer	4.53e-05	0.000317	CcSEcCtD
Everolimus—Connective tissue disorder—Epirubicin—urinary bladder cancer	4.53e-05	0.000317	CcSEcCtD
Everolimus—Urethral disorder—Epirubicin—urinary bladder cancer	4.51e-05	0.000316	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—ERBB2—urinary bladder cancer	4.51e-05	0.000683	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—EGFR—urinary bladder cancer	4.5e-05	0.000683	CbGpPWpGaD
Everolimus—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	4.49e-05	0.000314	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—HDAC4—urinary bladder cancer	4.48e-05	0.00068	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—EGFR—urinary bladder cancer	4.48e-05	0.00068	CbGpPWpGaD
Everolimus—Epistaxis—Doxorubicin—urinary bladder cancer	4.48e-05	0.000313	CcSEcCtD
Everolimus—Angiopathy—Methotrexate—urinary bladder cancer	4.47e-05	0.000312	CcSEcCtD
Everolimus—Sinusitis—Doxorubicin—urinary bladder cancer	4.45e-05	0.000312	CcSEcCtD
Everolimus—Immune system disorder—Methotrexate—urinary bladder cancer	4.45e-05	0.000311	CcSEcCtD
Everolimus—Dizziness—Fluorouracil—urinary bladder cancer	4.44e-05	0.000311	CcSEcCtD
Everolimus—Mediastinal disorder—Methotrexate—urinary bladder cancer	4.44e-05	0.00031	CcSEcCtD
Everolimus—Chills—Methotrexate—urinary bladder cancer	4.42e-05	0.000309	CcSEcCtD
Everolimus—MTOR—Signaling by SCF-KIT—HRAS—urinary bladder cancer	4.42e-05	0.000669	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	4.37e-05	0.000663	CbGpPWpGaD
Everolimus—Diarrhoea—Cisplatin—urinary bladder cancer	4.36e-05	0.000305	CcSEcCtD
Everolimus—Alopecia—Methotrexate—urinary bladder cancer	4.35e-05	0.000304	CcSEcCtD
Everolimus—Vomiting—Gemcitabine—urinary bladder cancer	4.35e-05	0.000304	CcSEcCtD
Everolimus—MTOR—BDNF signaling pathway—HRAS—urinary bladder cancer	4.34e-05	0.000658	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—KRAS—urinary bladder cancer	4.33e-05	0.000656	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—KRAS—urinary bladder cancer	4.33e-05	0.000656	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—urinary bladder cancer	4.33e-05	0.000656	CbGpPWpGaD
Everolimus—Mental disorder—Methotrexate—urinary bladder cancer	4.31e-05	0.000302	CcSEcCtD
Everolimus—Rash—Gemcitabine—urinary bladder cancer	4.31e-05	0.000302	CcSEcCtD
Everolimus—Dermatitis—Gemcitabine—urinary bladder cancer	4.31e-05	0.000301	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—TSC1—urinary bladder cancer	4.31e-05	0.000653	CbGpPWpGaD
Everolimus—Eye disorder—Epirubicin—urinary bladder cancer	4.3e-05	0.000301	CcSEcCtD
Everolimus—Hypersensitivity—Etoposide—urinary bladder cancer	4.3e-05	0.000301	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—KRAS—urinary bladder cancer	4.29e-05	0.000651	CbGpPWpGaD
Everolimus—Erythema—Methotrexate—urinary bladder cancer	4.28e-05	0.0003	CcSEcCtD
Everolimus—Malnutrition—Methotrexate—urinary bladder cancer	4.28e-05	0.0003	CcSEcCtD
Everolimus—Haemoglobin—Doxorubicin—urinary bladder cancer	4.28e-05	0.0003	CcSEcCtD
Everolimus—Headache—Gemcitabine—urinary bladder cancer	4.28e-05	0.0003	CcSEcCtD
Everolimus—Cardiac disorder—Epirubicin—urinary bladder cancer	4.27e-05	0.000299	CcSEcCtD
Everolimus—Flushing—Epirubicin—urinary bladder cancer	4.27e-05	0.000299	CcSEcCtD
Everolimus—Vomiting—Fluorouracil—urinary bladder cancer	4.27e-05	0.000299	CcSEcCtD
Everolimus—Rhinitis—Doxorubicin—urinary bladder cancer	4.27e-05	0.000299	CcSEcCtD
Everolimus—FKBP1A—Disease—NCOR1—urinary bladder cancer	4.26e-05	0.000646	CbGpPWpGaD
Everolimus—Hepatitis—Doxorubicin—urinary bladder cancer	4.26e-05	0.000298	CcSEcCtD
Everolimus—Haemorrhage—Doxorubicin—urinary bladder cancer	4.26e-05	0.000298	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—KRAS—urinary bladder cancer	4.25e-05	0.000645	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—EGFR—urinary bladder cancer	4.24e-05	0.000643	CbGpPWpGaD
Everolimus—Hypoaesthesia—Doxorubicin—urinary bladder cancer	4.24e-05	0.000297	CcSEcCtD
Everolimus—Rash—Fluorouracil—urinary bladder cancer	4.24e-05	0.000297	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—KRAS—urinary bladder cancer	4.24e-05	0.000642	CbGpPWpGaD
Everolimus—Dermatitis—Fluorouracil—urinary bladder cancer	4.23e-05	0.000296	CcSEcCtD
Everolimus—Pharyngitis—Doxorubicin—urinary bladder cancer	4.23e-05	0.000296	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—HRAS—urinary bladder cancer	4.23e-05	0.00064	CbGpPWpGaD
Everolimus—Headache—Fluorouracil—urinary bladder cancer	4.21e-05	0.000295	CcSEcCtD
Everolimus—Urinary tract disorder—Doxorubicin—urinary bladder cancer	4.21e-05	0.000295	CcSEcCtD
Everolimus—Oedema peripheral—Doxorubicin—urinary bladder cancer	4.2e-05	0.000294	CcSEcCtD
Everolimus—Dysgeusia—Methotrexate—urinary bladder cancer	4.2e-05	0.000294	CcSEcCtD
Everolimus—Asthenia—Etoposide—urinary bladder cancer	4.19e-05	0.000293	CcSEcCtD
Everolimus—Connective tissue disorder—Doxorubicin—urinary bladder cancer	4.19e-05	0.000293	CcSEcCtD
Everolimus—Angiopathy—Epirubicin—urinary bladder cancer	4.18e-05	0.000292	CcSEcCtD
Everolimus—Urethral disorder—Doxorubicin—urinary bladder cancer	4.18e-05	0.000292	CcSEcCtD
Everolimus—Immune system disorder—Epirubicin—urinary bladder cancer	4.16e-05	0.000291	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—HRAS—urinary bladder cancer	4.16e-05	0.00063	CbGpPWpGaD
Everolimus—Mediastinal disorder—Epirubicin—urinary bladder cancer	4.15e-05	0.00029	CcSEcCtD
Everolimus—Back pain—Methotrexate—urinary bladder cancer	4.14e-05	0.00029	CcSEcCtD
Everolimus—Chills—Epirubicin—urinary bladder cancer	4.13e-05	0.000289	CcSEcCtD
Everolimus—Pruritus—Etoposide—urinary bladder cancer	4.13e-05	0.000289	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—CDKN1A—urinary bladder cancer	4.11e-05	0.000622	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—JAG1—urinary bladder cancer	4.1e-05	0.000621	CbGpPWpGaD
Everolimus—Alopecia—Epirubicin—urinary bladder cancer	4.07e-05	0.000285	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—urinary bladder cancer	4.06e-05	0.000615	CbGpPWpGaD
Everolimus—Nausea—Gemcitabine—urinary bladder cancer	4.06e-05	0.000284	CcSEcCtD
Everolimus—Vomiting—Cisplatin—urinary bladder cancer	4.05e-05	0.000284	CcSEcCtD
Everolimus—Vision blurred—Methotrexate—urinary bladder cancer	4.04e-05	0.000283	CcSEcCtD
Everolimus—Mental disorder—Epirubicin—urinary bladder cancer	4.04e-05	0.000282	CcSEcCtD
Everolimus—Rash—Cisplatin—urinary bladder cancer	4.02e-05	0.000281	CcSEcCtD
Everolimus—Dermatitis—Cisplatin—urinary bladder cancer	4.01e-05	0.000281	CcSEcCtD
Everolimus—Erythema—Epirubicin—urinary bladder cancer	4.01e-05	0.000281	CcSEcCtD
Everolimus—Malnutrition—Epirubicin—urinary bladder cancer	4.01e-05	0.000281	CcSEcCtD
Everolimus—MTOR—B Cell Activation—KRAS—urinary bladder cancer	4.01e-05	0.000608	CbGpPWpGaD
Everolimus—FKBP1A—Disease—ERCC2—urinary bladder cancer	4.01e-05	0.000607	CbGpPWpGaD
Everolimus—Diarrhoea—Etoposide—urinary bladder cancer	3.99e-05	0.00028	CcSEcCtD
Everolimus—Nausea—Fluorouracil—urinary bladder cancer	3.99e-05	0.000279	CcSEcCtD
Everolimus—MTOR—Insulin Signaling—HRAS—urinary bladder cancer	3.99e-05	0.000605	CbGpPWpGaD
Everolimus—MTOR—Immune System—RBX1—urinary bladder cancer	3.98e-05	0.000604	CbGpPWpGaD
Everolimus—Eye disorder—Doxorubicin—urinary bladder cancer	3.98e-05	0.000279	CcSEcCtD
Everolimus—Ill-defined disorder—Methotrexate—urinary bladder cancer	3.98e-05	0.000278	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—HRAS—urinary bladder cancer	3.97e-05	0.000602	CbGpPWpGaD
Everolimus—Anaemia—Methotrexate—urinary bladder cancer	3.96e-05	0.000277	CcSEcCtD
Everolimus—Cardiac disorder—Doxorubicin—urinary bladder cancer	3.96e-05	0.000277	CcSEcCtD
Everolimus—Flushing—Doxorubicin—urinary bladder cancer	3.96e-05	0.000277	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—HRAS—urinary bladder cancer	3.95e-05	0.000599	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—urinary bladder cancer	3.95e-05	0.000599	CbGpPWpGaD
Everolimus—Flatulence—Epirubicin—urinary bladder cancer	3.95e-05	0.000276	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—HRAS—urinary bladder cancer	3.93e-05	0.000596	CbGpPWpGaD
Everolimus—Dysgeusia—Epirubicin—urinary bladder cancer	3.93e-05	0.000275	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—HRAS—urinary bladder cancer	3.91e-05	0.000593	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—EP300—urinary bladder cancer	3.91e-05	0.000592	CbGpPWpGaD
Everolimus—MTOR—Disease—ENO2—urinary bladder cancer	3.88e-05	0.000588	CbGpPWpGaD
Everolimus—Back pain—Epirubicin—urinary bladder cancer	3.88e-05	0.000271	CcSEcCtD
Everolimus—Angiopathy—Doxorubicin—urinary bladder cancer	3.87e-05	0.000271	CcSEcCtD
Everolimus—Malaise—Methotrexate—urinary bladder cancer	3.86e-05	0.00027	CcSEcCtD
Everolimus—Dizziness—Etoposide—urinary bladder cancer	3.86e-05	0.00027	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—urinary bladder cancer	3.86e-05	0.000585	CbGpPWpGaD
Everolimus—Muscle spasms—Epirubicin—urinary bladder cancer	3.85e-05	0.00027	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—CDKN1A—urinary bladder cancer	3.85e-05	0.000584	CbGpPWpGaD
Everolimus—Immune system disorder—Doxorubicin—urinary bladder cancer	3.85e-05	0.000269	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—PTEN—urinary bladder cancer	3.84e-05	0.000582	CbGpPWpGaD
Everolimus—Mediastinal disorder—Doxorubicin—urinary bladder cancer	3.84e-05	0.000269	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—urinary bladder cancer	3.84e-05	0.000581	CbGpPWpGaD
Everolimus—Leukopenia—Methotrexate—urinary bladder cancer	3.83e-05	0.000268	CcSEcCtD
Everolimus—Chills—Doxorubicin—urinary bladder cancer	3.82e-05	0.000268	CcSEcCtD
Everolimus—Nausea—Cisplatin—urinary bladder cancer	3.78e-05	0.000265	CcSEcCtD
Everolimus—Vision blurred—Epirubicin—urinary bladder cancer	3.78e-05	0.000264	CcSEcCtD
Everolimus—FKBP1A—Disease—MTHFR—urinary bladder cancer	3.77e-05	0.000571	CbGpPWpGaD
Everolimus—Alopecia—Doxorubicin—urinary bladder cancer	3.77e-05	0.000264	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—GLI1—urinary bladder cancer	3.76e-05	0.00057	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TERT—urinary bladder cancer	3.76e-05	0.000569	CbGpPWpGaD
Everolimus—Cough—Methotrexate—urinary bladder cancer	3.74e-05	0.000262	CcSEcCtD
Everolimus—Mental disorder—Doxorubicin—urinary bladder cancer	3.73e-05	0.000261	CcSEcCtD
Everolimus—Ill-defined disorder—Epirubicin—urinary bladder cancer	3.72e-05	0.00026	CcSEcCtD
Everolimus—Convulsion—Methotrexate—urinary bladder cancer	3.71e-05	0.00026	CcSEcCtD
Everolimus—Vomiting—Etoposide—urinary bladder cancer	3.71e-05	0.00026	CcSEcCtD
Everolimus—Erythema—Doxorubicin—urinary bladder cancer	3.71e-05	0.00026	CcSEcCtD
Everolimus—Malnutrition—Doxorubicin—urinary bladder cancer	3.71e-05	0.00026	CcSEcCtD
Everolimus—Anaemia—Epirubicin—urinary bladder cancer	3.71e-05	0.000259	CcSEcCtD
Everolimus—Agitation—Epirubicin—urinary bladder cancer	3.68e-05	0.000258	CcSEcCtD
Everolimus—MTOR—DAP12 interactions—HRAS—urinary bladder cancer	3.68e-05	0.000558	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—urinary bladder cancer	3.68e-05	0.000558	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—HRAS—urinary bladder cancer	3.68e-05	0.000558	CbGpPWpGaD
Everolimus—Rash—Etoposide—urinary bladder cancer	3.68e-05	0.000258	CcSEcCtD
Everolimus—MTOR—Disease—RBX1—urinary bladder cancer	3.68e-05	0.000558	CbGpPWpGaD
Everolimus—Dermatitis—Etoposide—urinary bladder cancer	3.68e-05	0.000257	CcSEcCtD
Everolimus—Headache—Etoposide—urinary bladder cancer	3.66e-05	0.000256	CcSEcCtD
Everolimus—Flatulence—Doxorubicin—urinary bladder cancer	3.66e-05	0.000256	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—HRAS—urinary bladder cancer	3.65e-05	0.000553	CbGpPWpGaD
Everolimus—Chest pain—Methotrexate—urinary bladder cancer	3.65e-05	0.000255	CcSEcCtD
Everolimus—Myalgia—Methotrexate—urinary bladder cancer	3.65e-05	0.000255	CcSEcCtD
Everolimus—Arthralgia—Methotrexate—urinary bladder cancer	3.65e-05	0.000255	CcSEcCtD
Everolimus—Dysgeusia—Doxorubicin—urinary bladder cancer	3.63e-05	0.000254	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	3.62e-05	0.000253	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—HRAS—urinary bladder cancer	3.62e-05	0.000548	CbGpPWpGaD
Everolimus—Malaise—Epirubicin—urinary bladder cancer	3.62e-05	0.000253	CcSEcCtD
Everolimus—MTOR—Innate Immune System—FGFR3—urinary bladder cancer	3.6e-05	0.000546	CbGpPWpGaD
Everolimus—Discomfort—Methotrexate—urinary bladder cancer	3.6e-05	0.000252	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—HRAS—urinary bladder cancer	3.6e-05	0.000546	CbGpPWpGaD
Everolimus—Syncope—Epirubicin—urinary bladder cancer	3.6e-05	0.000252	CcSEcCtD
Everolimus—Leukopenia—Epirubicin—urinary bladder cancer	3.59e-05	0.000251	CcSEcCtD
Everolimus—Back pain—Doxorubicin—urinary bladder cancer	3.59e-05	0.000251	CcSEcCtD
Everolimus—Muscle spasms—Doxorubicin—urinary bladder cancer	3.57e-05	0.00025	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—SRC—urinary bladder cancer	3.56e-05	0.00054	CbGpPWpGaD
Everolimus—Palpitations—Epirubicin—urinary bladder cancer	3.54e-05	0.000248	CcSEcCtD
Everolimus—Loss of consciousness—Epirubicin—urinary bladder cancer	3.52e-05	0.000247	CcSEcCtD
Everolimus—Cough—Epirubicin—urinary bladder cancer	3.5e-05	0.000245	CcSEcCtD
Everolimus—Vision blurred—Doxorubicin—urinary bladder cancer	3.5e-05	0.000245	CcSEcCtD
Everolimus—Convulsion—Epirubicin—urinary bladder cancer	3.47e-05	0.000243	CcSEcCtD
Everolimus—Infection—Methotrexate—urinary bladder cancer	3.47e-05	0.000243	CcSEcCtD
Everolimus—Nausea—Etoposide—urinary bladder cancer	3.47e-05	0.000243	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—FGFR3—urinary bladder cancer	3.46e-05	0.000525	CbGpPWpGaD
Everolimus—Hypertension—Epirubicin—urinary bladder cancer	3.46e-05	0.000242	CcSEcCtD
Everolimus—FKBP1A—Disease—FGFR3—urinary bladder cancer	3.45e-05	0.000522	CbGpPWpGaD
Everolimus—Ill-defined disorder—Doxorubicin—urinary bladder cancer	3.44e-05	0.000241	CcSEcCtD
Everolimus—Nervous system disorder—Methotrexate—urinary bladder cancer	3.43e-05	0.00024	CcSEcCtD
Everolimus—Anaemia—Doxorubicin—urinary bladder cancer	3.43e-05	0.00024	CcSEcCtD
Everolimus—Thrombocytopenia—Methotrexate—urinary bladder cancer	3.42e-05	0.00024	CcSEcCtD
Everolimus—Arthralgia—Epirubicin—urinary bladder cancer	3.41e-05	0.000239	CcSEcCtD
Everolimus—Myalgia—Epirubicin—urinary bladder cancer	3.41e-05	0.000239	CcSEcCtD
Everolimus—Chest pain—Epirubicin—urinary bladder cancer	3.41e-05	0.000239	CcSEcCtD
Everolimus—Agitation—Doxorubicin—urinary bladder cancer	3.41e-05	0.000239	CcSEcCtD
Everolimus—MTOR—B Cell Activation—HRAS—urinary bladder cancer	3.41e-05	0.000516	CbGpPWpGaD
Everolimus—Anxiety—Epirubicin—urinary bladder cancer	3.4e-05	0.000238	CcSEcCtD
Everolimus—Skin disorder—Methotrexate—urinary bladder cancer	3.4e-05	0.000238	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	3.39e-05	0.000237	CcSEcCtD
Everolimus—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	3.39e-05	0.000514	CbGpPWpGaD
Everolimus—Hyperhidrosis—Methotrexate—urinary bladder cancer	3.38e-05	0.000237	CcSEcCtD
Everolimus—Discomfort—Epirubicin—urinary bladder cancer	3.37e-05	0.000236	CcSEcCtD
Everolimus—Malaise—Doxorubicin—urinary bladder cancer	3.35e-05	0.000234	CcSEcCtD
Everolimus—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.34e-05	0.000506	CbGpPWpGaD
Everolimus—Dry mouth—Epirubicin—urinary bladder cancer	3.34e-05	0.000234	CcSEcCtD
Everolimus—Anorexia—Methotrexate—urinary bladder cancer	3.33e-05	0.000233	CcSEcCtD
Everolimus—Syncope—Doxorubicin—urinary bladder cancer	3.33e-05	0.000233	CcSEcCtD
Everolimus—Leukopenia—Doxorubicin—urinary bladder cancer	3.32e-05	0.000232	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—S100B—urinary bladder cancer	3.32e-05	0.000503	CbGpPWpGaD
Everolimus—MTOR—Disease—JAG1—urinary bladder cancer	3.29e-05	0.000499	CbGpPWpGaD
Everolimus—Palpitations—Doxorubicin—urinary bladder cancer	3.28e-05	0.000229	CcSEcCtD
Everolimus—Oedema—Epirubicin—urinary bladder cancer	3.27e-05	0.000229	CcSEcCtD
Everolimus—Hypotension—Methotrexate—urinary bladder cancer	3.27e-05	0.000229	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—urinary bladder cancer	3.26e-05	0.000494	CbGpPWpGaD
Everolimus—Loss of consciousness—Doxorubicin—urinary bladder cancer	3.26e-05	0.000228	CcSEcCtD
Everolimus—Infection—Epirubicin—urinary bladder cancer	3.25e-05	0.000227	CcSEcCtD
Everolimus—Cough—Doxorubicin—urinary bladder cancer	3.24e-05	0.000227	CcSEcCtD
Everolimus—Shock—Epirubicin—urinary bladder cancer	3.22e-05	0.000225	CcSEcCtD
Everolimus—Convulsion—Doxorubicin—urinary bladder cancer	3.21e-05	0.000225	CcSEcCtD
Everolimus—Nervous system disorder—Epirubicin—urinary bladder cancer	3.21e-05	0.000225	CcSEcCtD
Everolimus—Thrombocytopenia—Epirubicin—urinary bladder cancer	3.2e-05	0.000224	CcSEcCtD
Everolimus—Hypertension—Doxorubicin—urinary bladder cancer	3.2e-05	0.000224	CcSEcCtD
Everolimus—Tachycardia—Epirubicin—urinary bladder cancer	3.19e-05	0.000223	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	3.19e-05	0.000223	CcSEcCtD
Everolimus—Skin disorder—Epirubicin—urinary bladder cancer	3.18e-05	0.000222	CcSEcCtD
Everolimus—Hyperhidrosis—Epirubicin—urinary bladder cancer	3.16e-05	0.000221	CcSEcCtD
Everolimus—Insomnia—Methotrexate—urinary bladder cancer	3.16e-05	0.000221	CcSEcCtD
Everolimus—Myalgia—Doxorubicin—urinary bladder cancer	3.16e-05	0.000221	CcSEcCtD
Everolimus—Chest pain—Doxorubicin—urinary bladder cancer	3.16e-05	0.000221	CcSEcCtD
Everolimus—Arthralgia—Doxorubicin—urinary bladder cancer	3.16e-05	0.000221	CcSEcCtD
Everolimus—Anxiety—Doxorubicin—urinary bladder cancer	3.15e-05	0.00022	CcSEcCtD
Everolimus—Paraesthesia—Methotrexate—urinary bladder cancer	3.14e-05	0.00022	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	3.14e-05	0.00022	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—EGFR—urinary bladder cancer	3.12e-05	0.000473	CbGpPWpGaD
Everolimus—Discomfort—Doxorubicin—urinary bladder cancer	3.12e-05	0.000218	CcSEcCtD
Everolimus—Anorexia—Epirubicin—urinary bladder cancer	3.12e-05	0.000218	CcSEcCtD
Everolimus—Dyspnoea—Methotrexate—urinary bladder cancer	3.12e-05	0.000218	CcSEcCtD
Everolimus—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	3.11e-05	0.000472	CbGpPWpGaD
Everolimus—Somnolence—Methotrexate—urinary bladder cancer	3.11e-05	0.000218	CcSEcCtD
Everolimus—Dry mouth—Doxorubicin—urinary bladder cancer	3.09e-05	0.000216	CcSEcCtD
Everolimus—Dyspepsia—Methotrexate—urinary bladder cancer	3.08e-05	0.000215	CcSEcCtD
Everolimus—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.07e-05	0.000465	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CREBBP—urinary bladder cancer	3.07e-05	0.000465	CbGpPWpGaD
Everolimus—Hypotension—Epirubicin—urinary bladder cancer	3.06e-05	0.000214	CcSEcCtD
Everolimus—MTOR—Immune System—IFNA2—urinary bladder cancer	3.05e-05	0.000463	CbGpPWpGaD
Everolimus—Decreased appetite—Methotrexate—urinary bladder cancer	3.04e-05	0.000213	CcSEcCtD
Everolimus—Oedema—Doxorubicin—urinary bladder cancer	3.03e-05	0.000212	CcSEcCtD
Everolimus—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	3.02e-05	0.000211	CcSEcCtD
Everolimus—Fatigue—Methotrexate—urinary bladder cancer	3.01e-05	0.000211	CcSEcCtD
Everolimus—Infection—Doxorubicin—urinary bladder cancer	3.01e-05	0.00021	CcSEcCtD
Everolimus—Pain—Methotrexate—urinary bladder cancer	2.99e-05	0.000209	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—NCOR1—urinary bladder cancer	2.98e-05	0.000452	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	2.98e-05	0.000209	CcSEcCtD
Everolimus—Shock—Doxorubicin—urinary bladder cancer	2.98e-05	0.000208	CcSEcCtD
Everolimus—Nervous system disorder—Doxorubicin—urinary bladder cancer	2.97e-05	0.000208	CcSEcCtD
Everolimus—Thrombocytopenia—Doxorubicin—urinary bladder cancer	2.96e-05	0.000207	CcSEcCtD
Everolimus—Insomnia—Epirubicin—urinary bladder cancer	2.96e-05	0.000207	CcSEcCtD
Everolimus—Tachycardia—Doxorubicin—urinary bladder cancer	2.95e-05	0.000207	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—KRAS—urinary bladder cancer	2.95e-05	0.000447	CbGpPWpGaD
Everolimus—Skin disorder—Doxorubicin—urinary bladder cancer	2.94e-05	0.000206	CcSEcCtD
Everolimus—Paraesthesia—Epirubicin—urinary bladder cancer	2.94e-05	0.000206	CcSEcCtD
Everolimus—FKBP1A—Disease—CREBBP—urinary bladder cancer	2.93e-05	0.000445	CbGpPWpGaD
Everolimus—Hyperhidrosis—Doxorubicin—urinary bladder cancer	2.93e-05	0.000205	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—CDH1—urinary bladder cancer	2.92e-05	0.000443	CbGpPWpGaD
Everolimus—Dyspnoea—Epirubicin—urinary bladder cancer	2.92e-05	0.000204	CcSEcCtD
Everolimus—Somnolence—Epirubicin—urinary bladder cancer	2.91e-05	0.000204	CcSEcCtD
Everolimus—MTOR—Immune System—S100B—urinary bladder cancer	2.89e-05	0.000438	CbGpPWpGaD
Everolimus—Anorexia—Doxorubicin—urinary bladder cancer	2.89e-05	0.000202	CcSEcCtD
Everolimus—Feeling abnormal—Methotrexate—urinary bladder cancer	2.88e-05	0.000202	CcSEcCtD
Everolimus—Dyspepsia—Epirubicin—urinary bladder cancer	2.88e-05	0.000202	CcSEcCtD
Everolimus—Gastrointestinal pain—Methotrexate—urinary bladder cancer	2.86e-05	0.0002	CcSEcCtD
Everolimus—Decreased appetite—Epirubicin—urinary bladder cancer	2.84e-05	0.000199	CcSEcCtD
Everolimus—Hypotension—Doxorubicin—urinary bladder cancer	2.83e-05	0.000198	CcSEcCtD
Everolimus—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	2.82e-05	0.000198	CcSEcCtD
Everolimus—Fatigue—Epirubicin—urinary bladder cancer	2.82e-05	0.000197	CcSEcCtD
Everolimus—Pain—Epirubicin—urinary bladder cancer	2.8e-05	0.000196	CcSEcCtD
Everolimus—Constipation—Epirubicin—urinary bladder cancer	2.8e-05	0.000196	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—TP53—urinary bladder cancer	2.8e-05	0.000424	CbGpPWpGaD
Everolimus—Body temperature increased—Methotrexate—urinary bladder cancer	2.76e-05	0.000193	CcSEcCtD
Everolimus—Abdominal pain—Methotrexate—urinary bladder cancer	2.76e-05	0.000193	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	2.76e-05	0.000193	CcSEcCtD
Everolimus—Insomnia—Doxorubicin—urinary bladder cancer	2.74e-05	0.000192	CcSEcCtD
Everolimus—Paraesthesia—Doxorubicin—urinary bladder cancer	2.72e-05	0.00019	CcSEcCtD
Everolimus—Dyspnoea—Doxorubicin—urinary bladder cancer	2.7e-05	0.000189	CcSEcCtD
Everolimus—Feeling abnormal—Epirubicin—urinary bladder cancer	2.7e-05	0.000189	CcSEcCtD
Everolimus—Somnolence—Doxorubicin—urinary bladder cancer	2.69e-05	0.000188	CcSEcCtD
Everolimus—Gastrointestinal pain—Epirubicin—urinary bladder cancer	2.68e-05	0.000187	CcSEcCtD
Everolimus—Dyspepsia—Doxorubicin—urinary bladder cancer	2.67e-05	0.000187	CcSEcCtD
Everolimus—FKBP1A—Disease—RHOA—urinary bladder cancer	2.65e-05	0.000402	CbGpPWpGaD
Everolimus—Decreased appetite—Doxorubicin—urinary bladder cancer	2.63e-05	0.000184	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—TERT—urinary bladder cancer	2.63e-05	0.000399	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	2.61e-05	0.000183	CcSEcCtD
Everolimus—Fatigue—Doxorubicin—urinary bladder cancer	2.61e-05	0.000183	CcSEcCtD
Everolimus—Constipation—Doxorubicin—urinary bladder cancer	2.59e-05	0.000181	CcSEcCtD
Everolimus—Pain—Doxorubicin—urinary bladder cancer	2.59e-05	0.000181	CcSEcCtD
Everolimus—Abdominal pain—Epirubicin—urinary bladder cancer	2.59e-05	0.000181	CcSEcCtD
Everolimus—Body temperature increased—Epirubicin—urinary bladder cancer	2.59e-05	0.000181	CcSEcCtD
Everolimus—Hypersensitivity—Methotrexate—urinary bladder cancer	2.58e-05	0.00018	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—RBX1—urinary bladder cancer	2.58e-05	0.00039	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—ERBB2—urinary bladder cancer	2.57e-05	0.00039	CbGpPWpGaD
Everolimus—Asthenia—Methotrexate—urinary bladder cancer	2.51e-05	0.000176	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—HRAS—urinary bladder cancer	2.51e-05	0.00038	CbGpPWpGaD
Everolimus—Feeling abnormal—Doxorubicin—urinary bladder cancer	2.49e-05	0.000175	CcSEcCtD
Everolimus—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.48e-05	0.000173	CcSEcCtD
Everolimus—Pruritus—Methotrexate—urinary bladder cancer	2.47e-05	0.000173	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—ERBB2—urinary bladder cancer	2.47e-05	0.000374	CbGpPWpGaD
Everolimus—FKBP1A—Disease—ERBB2—urinary bladder cancer	2.46e-05	0.000372	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TSC1—urinary bladder cancer	2.42e-05	0.000367	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGFR3—urinary bladder cancer	2.41e-05	0.000366	CbGpPWpGaD
Everolimus—Hypersensitivity—Epirubicin—urinary bladder cancer	2.41e-05	0.000169	CcSEcCtD
Everolimus—FKBP1A—Disease—PTGS2—urinary bladder cancer	2.4e-05	0.000364	CbGpPWpGaD
Everolimus—MTOR—Disease—NCOR1—urinary bladder cancer	2.4e-05	0.000363	CbGpPWpGaD
Everolimus—Abdominal pain—Doxorubicin—urinary bladder cancer	2.39e-05	0.000167	CcSEcCtD
Everolimus—Body temperature increased—Doxorubicin—urinary bladder cancer	2.39e-05	0.000167	CcSEcCtD
Everolimus—Diarrhoea—Methotrexate—urinary bladder cancer	2.39e-05	0.000167	CcSEcCtD
Everolimus—Asthenia—Epirubicin—urinary bladder cancer	2.35e-05	0.000164	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—ESR1—urinary bladder cancer	2.34e-05	0.000355	CbGpPWpGaD
Everolimus—Pruritus—Epirubicin—urinary bladder cancer	2.32e-05	0.000162	CcSEcCtD
Everolimus—Dizziness—Methotrexate—urinary bladder cancer	2.31e-05	0.000162	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—JAG1—urinary bladder cancer	2.31e-05	0.000349	CbGpPWpGaD
Everolimus—MTOR—Disease—ERCC2—urinary bladder cancer	2.25e-05	0.000342	CbGpPWpGaD
Everolimus—Diarrhoea—Epirubicin—urinary bladder cancer	2.24e-05	0.000157	CcSEcCtD
Everolimus—Hypersensitivity—Doxorubicin—urinary bladder cancer	2.23e-05	0.000156	CcSEcCtD
Everolimus—Vomiting—Methotrexate—urinary bladder cancer	2.22e-05	0.000156	CcSEcCtD
Everolimus—Rash—Methotrexate—urinary bladder cancer	2.2e-05	0.000154	CcSEcCtD
Everolimus—Dermatitis—Methotrexate—urinary bladder cancer	2.2e-05	0.000154	CcSEcCtD
Everolimus—MTOR—Innate Immune System—CDKN1A—urinary bladder cancer	2.2e-05	0.000333	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PTEN—urinary bladder cancer	2.19e-05	0.000332	CbGpPWpGaD
Everolimus—Headache—Methotrexate—urinary bladder cancer	2.19e-05	0.000153	CcSEcCtD
Everolimus—Asthenia—Doxorubicin—urinary bladder cancer	2.17e-05	0.000152	CcSEcCtD
Everolimus—Dizziness—Epirubicin—urinary bladder cancer	2.16e-05	0.000151	CcSEcCtD
Everolimus—Pruritus—Doxorubicin—urinary bladder cancer	2.14e-05	0.00015	CcSEcCtD
Everolimus—MTOR—Disease—MTHFR—urinary bladder cancer	2.12e-05	0.000321	CbGpPWpGaD
Everolimus—MTOR—Disease—TERT—urinary bladder cancer	2.11e-05	0.00032	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDKN1A—urinary bladder cancer	2.11e-05	0.00032	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PTEN—urinary bladder cancer	2.1e-05	0.000319	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CDKN1A—urinary bladder cancer	2.1e-05	0.000318	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGFR3—urinary bladder cancer	2.1e-05	0.000318	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTEN—urinary bladder cancer	2.1e-05	0.000318	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EP300—urinary bladder cancer	2.09e-05	0.000317	CbGpPWpGaD
Everolimus—Vomiting—Epirubicin—urinary bladder cancer	2.08e-05	0.000146	CcSEcCtD
Everolimus—Nausea—Methotrexate—urinary bladder cancer	2.08e-05	0.000145	CcSEcCtD
Everolimus—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.08e-05	0.000315	CbGpPWpGaD
Everolimus—Diarrhoea—Doxorubicin—urinary bladder cancer	2.07e-05	0.000145	CcSEcCtD
Everolimus—Rash—Epirubicin—urinary bladder cancer	2.06e-05	0.000144	CcSEcCtD
Everolimus—Dermatitis—Epirubicin—urinary bladder cancer	2.06e-05	0.000144	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CREBBP—urinary bladder cancer	2.05e-05	0.000311	CbGpPWpGaD
Everolimus—Headache—Epirubicin—urinary bladder cancer	2.05e-05	0.000143	CcSEcCtD
Everolimus—MTOR—Innate Immune System—SRC—urinary bladder cancer	2.03e-05	0.000308	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IGF1—urinary bladder cancer	2.03e-05	0.000308	CbGpPWpGaD
Everolimus—Dizziness—Doxorubicin—urinary bladder cancer	2e-05	0.00014	CcSEcCtD
Everolimus—FKBP1A—Disease—EP300—urinary bladder cancer	2e-05	0.000303	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.97e-05	0.000298	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.97e-05	0.000298	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—SRC—urinary bladder cancer	1.95e-05	0.000296	CbGpPWpGaD
Everolimus—Nausea—Epirubicin—urinary bladder cancer	1.94e-05	0.000136	CcSEcCtD
Everolimus—FKBP1A—Disease—SRC—urinary bladder cancer	1.94e-05	0.000295	CbGpPWpGaD
Everolimus—MTOR—Disease—FGFR3—urinary bladder cancer	1.94e-05	0.000294	CbGpPWpGaD
Everolimus—Vomiting—Doxorubicin—urinary bladder cancer	1.93e-05	0.000135	CcSEcCtD
Everolimus—Rash—Doxorubicin—urinary bladder cancer	1.91e-05	0.000134	CcSEcCtD
Everolimus—Dermatitis—Doxorubicin—urinary bladder cancer	1.91e-05	0.000133	CcSEcCtD
Everolimus—Headache—Doxorubicin—urinary bladder cancer	1.9e-05	0.000133	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—S100B—urinary bladder cancer	1.87e-05	0.000283	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RHOA—urinary bladder cancer	1.86e-05	0.000282	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.8e-05	0.000273	CbGpPWpGaD
Everolimus—Nausea—Doxorubicin—urinary bladder cancer	1.8e-05	0.000126	CcSEcCtD
Everolimus—MTOR—Immune System—CREBBP—urinary bladder cancer	1.79e-05	0.000271	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EGFR—urinary bladder cancer	1.78e-05	0.00027	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDH1—urinary bladder cancer	1.77e-05	0.000269	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MYC—urinary bladder cancer	1.74e-05	0.000264	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.72e-05	0.000261	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGFR—urinary bladder cancer	1.71e-05	0.000259	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGFR—urinary bladder cancer	1.7e-05	0.000258	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—KRAS—urinary bladder cancer	1.68e-05	0.000255	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NCOR1—urinary bladder cancer	1.68e-05	0.000254	CbGpPWpGaD
Everolimus—MTOR—Disease—CREBBP—urinary bladder cancer	1.65e-05	0.00025	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCL8—urinary bladder cancer	1.63e-05	0.000247	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.62e-05	0.000246	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KRAS—urinary bladder cancer	1.62e-05	0.000245	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KRAS—urinary bladder cancer	1.61e-05	0.000244	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL2—urinary bladder cancer	1.56e-05	0.000236	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.53e-05	0.000232	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCND1—urinary bladder cancer	1.52e-05	0.00023	CbGpPWpGaD
Everolimus—MTOR—Immune System—ERBB2—urinary bladder cancer	1.5e-05	0.000227	CbGpPWpGaD
Everolimus—MTOR—Disease—RHOA—urinary bladder cancer	1.49e-05	0.000226	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.49e-05	0.000226	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TERT—urinary bladder cancer	1.48e-05	0.000224	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—urinary bladder cancer	1.48e-05	0.000224	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.47e-05	0.000223	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTEN—urinary bladder cancer	1.47e-05	0.000222	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HRAS—urinary bladder cancer	1.43e-05	0.000217	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EP300—urinary bladder cancer	1.4e-05	0.000212	CbGpPWpGaD
Everolimus—MTOR—Disease—ERBB2—urinary bladder cancer	1.38e-05	0.000209	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HRAS—urinary bladder cancer	1.37e-05	0.000208	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HRAS—urinary bladder cancer	1.37e-05	0.000207	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SRC—urinary bladder cancer	1.36e-05	0.000206	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGFR3—urinary bladder cancer	1.36e-05	0.000206	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL2—urinary bladder cancer	1.36e-05	0.000206	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—urinary bladder cancer	1.35e-05	0.000205	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ESR1—urinary bladder cancer	1.32e-05	0.0002	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDKN1A—urinary bladder cancer	1.28e-05	0.000194	CbGpPWpGaD
Everolimus—MTOR—Immune System—PTEN—urinary bladder cancer	1.28e-05	0.000193	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MYC—urinary bladder cancer	1.22e-05	0.000185	CbGpPWpGaD
Everolimus—MTOR—Immune System—EP300—urinary bladder cancer	1.22e-05	0.000185	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGFR—urinary bladder cancer	1.19e-05	0.000181	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.19e-05	0.000181	CbGpPWpGaD
Everolimus—MTOR—Immune System—SRC—urinary bladder cancer	1.18e-05	0.000179	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN1A—urinary bladder cancer	1.18e-05	0.000179	CbGpPWpGaD
Everolimus—MTOR—Disease—PTEN—urinary bladder cancer	1.18e-05	0.000179	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CREBBP—urinary bladder cancer	1.16e-05	0.000175	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF1—urinary bladder cancer	1.14e-05	0.000173	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KRAS—urinary bladder cancer	1.13e-05	0.000171	CbGpPWpGaD
Everolimus—MTOR—Disease—EP300—urinary bladder cancer	1.12e-05	0.00017	CbGpPWpGaD
Everolimus—MTOR—Disease—SRC—urinary bladder cancer	1.09e-05	0.000166	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.08e-05	0.000163	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RHOA—urinary bladder cancer	1.05e-05	0.000158	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGFR—urinary bladder cancer	1.04e-05	0.000157	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—urinary bladder cancer	1e-05	0.000152	CbGpPWpGaD
Everolimus—MTOR—Immune System—KRAS—urinary bladder cancer	9.8e-06	0.000149	CbGpPWpGaD
Everolimus—MTOR—Disease—MYC—urinary bladder cancer	9.79e-06	0.000148	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ERBB2—urinary bladder cancer	9.68e-06	0.000147	CbGpPWpGaD
Everolimus—MTOR—Disease—EGFR—urinary bladder cancer	9.58e-06	0.000145	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HRAS—urinary bladder cancer	9.58e-06	0.000145	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—RRM2—urinary bladder cancer	9.31e-06	0.000141	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL8—urinary bladder cancer	9.18e-06	0.000139	CbGpPWpGaD
Everolimus—MTOR—Disease—KRAS—urinary bladder cancer	9.05e-06	0.000137	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2—urinary bladder cancer	8.77e-06	0.000133	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ENO2—urinary bladder cancer	8.62e-06	0.000131	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	8.62e-06	0.000131	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCND1—urinary bladder cancer	8.55e-06	0.00013	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	8.36e-06	0.000127	CbGpPWpGaD
Everolimus—MTOR—Immune System—HRAS—urinary bladder cancer	8.33e-06	0.000126	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—urinary bladder cancer	8.3e-06	0.000126	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN1A—urinary bladder cancer	8.27e-06	0.000125	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTEN—urinary bladder cancer	8.25e-06	0.000125	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EP300—urinary bladder cancer	7.87e-06	0.000119	CbGpPWpGaD
Everolimus—MTOR—Disease—HRAS—urinary bladder cancer	7.69e-06	0.000117	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SRC—urinary bladder cancer	7.65e-06	0.000116	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NQO1—urinary bladder cancer	6.95e-06	0.000105	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MYC—urinary bladder cancer	6.86e-06	0.000104	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGFR—urinary bladder cancer	6.71e-06	0.000102	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KRAS—urinary bladder cancer	6.34e-06	9.61e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	5.79e-06	8.78e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—urinary bladder cancer	5.63e-06	8.54e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TYMS—urinary bladder cancer	5.39e-06	8.16e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HRAS—urinary bladder cancer	5.39e-06	8.16e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	5.32e-06	8.07e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	5.32e-06	8.07e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.1e-06	7.73e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.01e-06	7.59e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	4.71e-06	7.13e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARG—urinary bladder cancer	3.82e-06	5.78e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.67e-06	5.56e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3e-06	4.55e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.62e-06	3.97e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.5e-06	3.78e-05	CbGpPWpGaD
